Hemay Pharmaceutical Completes Nearly RMB 300 Million Series D Financing to Advance Innovative Drug Pipeline for "More Effective, Safer, and More Affordable Medicines"

Recently, Ganzhou Hemay Pharmaceutical Co., Ltd. (hereinafter referred to as "Hemay") announced the completion of its Series D financing, with a total funding amount of nearly RMB 300 million. This round was led by Hongfu Asset, with participation from renowned institutions and industry funds including Jihan Investment, Fakong Industrial Investment, Taikun Investment, and Anxin Guosheng Weixin Fund. Sanjiang Capital served as the exclusive financial advisor for this transaction.

Previously, HEMAY had secured multiple rounds of investment from renowned institutions including Legend Capital, Qianji Capital, Truman, Tigermed Investment, Yifeng Capital, Zhenzhuo Capital, DT Capital Partners, and Orient Alpha, with cumulative financing nearing RMB 1 billion.

The proceeds from this financing round will be primarily used to accelerate clinical trials for multiple drug candidates and indications, new drug registration, commercialization planning, and industrial implementation.

HEMAY is a pharmaceutical company dedicated to the global research and development of innovative drugs. Guided by its mission to “develop new drugs that are more effective, safer, and more affordable for patients,” the company has established a comprehensive system for the R&D and manufacturing of innovative therapeutics. HEMAY focuses primarily on developing First-in-Class (FIC), Best-in-Class (BIC), and Only-in-Class (OIC) candidates, with deep expertise in the fields of autoimmune diseases and malignant tumors. Its pipeline covers dozens of indications, including psoriasis, Behçet’s disease, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis (eczema), chronic obstructive pulmonary disease, inflammatory bowel disease (ulcerative colitis and Crohn’s disease), ankylosing spondylitis, breast cancer, non-small cell lung cancer, and solid tumors, thereby building a robust and diverse product portfolio.

The Company currently has two drug candidates with three indications in Phase III clinical trials. Among them, the core period of the Phase III clinical trial for Hemay005, a small-molecule PDE4 inhibitor for psoriasis, has been completed, and Hemay005 has been granted Orphan Drug Designation (“ODD”) by the FDA for the treatment of Behçet’s disease. Two additional drug candidates have completed or voluntarily concluded their Phase II clinical trials early and are poised to enter Phase III clinical trials. Furthermore, several other drug candidates and indications are in various stages of development, including Phase II, Phase I, clearance to commence clinical trials, or acceptance of clinical trial applications. Meanwhile, the Company’s core technology platforms and key drug candidates demonstrate strong potential for derivative product development and indication expansion. Consequently, expectations for the continuous launch of new products and new indications are highly optimistic, and the robust product pipeline and project reserves provide sustained and strong support and drive for the Company’s valuation.

The Company has currently established a relatively complete industrial chain, equipped with both hardware and software capabilities spanning early-stage new drug discovery, preclinical/clinical R&D and management, active pharmaceutical ingredient (API) and intermediate preparation, and formulation production. This infrastructure includes the Tianjin R&D Base (responsible for basic research and early-stage development of pipeline candidates), the Jian Xiajiang Production Base (for intermediates and APIs), and the Ganzhou Xinfeng Production Base (for formulations), providing a solid foundation for the continuous R&D and successful commercialization of the Company’s new drug candidates.

The company’s management team possesses nearly 20 years of professional experience across key processes, including new drug research and development, product registration, operational management, and business development. The team is characterized by its stability and strong cohesion. Meanwhile, the company’s Advisory Committee comprises renowned scholars from both domestic and international institutions, senior regulatory review experts, pioneers in the field of international respiratory medicine, internationally acclaimed academic leaders in respiratory science, and preclinical medical specialists. This committee provides continuous and efficient support for the company’s strategic direction, clinical planning, and other critical initiatives.

Founder/CEO: Zhang HeshengHe stated: “First and foremost, we extend our sincere gratitude to the investors in this round, as well as to all shareholders, friends, and partners who have recognized Hemay’s philosophy, products, and team throughout our development journey, for their invaluable assistance and support. Hemay has always adhered to the fundamental principle that the core value of a new drug R&D enterprise lies in the value of its products—specifically, in delivering ‘more effective, safer, and more affordable’ new medicines to patients. With the support from all parties and the relentless efforts of our team, Hemay has built a robust pipeline of new drug candidates with global competitiveness. While accelerating the market launch of existing products to benefit patients, Hemay remains committed to continuous innovation and the development of high-quality medicines.”

We would also like to extend our special gratitude to the team at Sanjiang Capital for their dedication and hard work. Navigating the ups and downs of the capital markets, our collaboration with Sanjiang Capital has allowed us to engage with true investment banking professionals. During their tenure as the exclusive financial advisor for the company’s two rounds of financing, the Sanjiang team demonstrated a high degree of responsibility, professional expertise, and resilience. Their execution capabilities and holistic strategic oversight left a deep impression on us. Sanjiang is a trustworthy strategic partner.”

Dr. Yang Zhichun, Partner at Hongfu Asset Management“Biopharmaceuticals represent a key area of high interest for Hongfu Assets. Hemay boasts a robust product pipeline covering therapeutic areas with significant unmet clinical needs, such as autoimmune diseases and oncology. The company’s most advanced candidate, Hemay005, is approaching the completion of its blinded data review. Current clinical data indicate that Hemay005, as a next-generation PDE4 inhibitor, demonstrates excellent safety and efficacy. The Hemay R&D team exhibits exceptional innovation and translational research capabilities. The company has independently developed various unique animal models, providing more reliable tools for the efficient screening of drug candidates in preclinical stages. Hemay’s proprietary platform technologies hold promise for delivering novel breakthroughs in cancer treatment. Hemay007 and Hemay181 are prime examples of the team’s innovative prowess. Hongfu Assets is honored to serve as the lead investor in this round of financing for Hemay, and we look forward to the early market launch of Hemay’s products to benefit a broad patient population.”

Mr. Jin Yilun, Managing Partner of Sanjiang Capital“Sanjiang Capital is honored to have served as the exclusive financial advisor for HEMAY’s Series C and Series D financing rounds. Under the leadership of Dr. Zhang and his core team, HEMAY has grown into a platform company with a comprehensive innovative drug R&D system and the capability to continuously deliver new drug products. After years of steady accumulation, HEMAY is now reaping the fruits of its efforts. We believe that under Dr. Zhang’s leadership, HEMAY will continue to address unmet clinical needs, establish itself in China while targeting the global market, and consistently benefit a broad patient population.”

Sanjiang Capital is China’s earliest new-generation investment bank dedicated to the biotechnology and healthcare sectors, with business coverage spanning sub-sectors such as biotechnology, pharmaceuticals, medical devices, healthcare services, and digital health. Founded in early 2008 by several senior bankers from top-tier international investment banks, the firm is headquartered in Shanghai. Sanjiang Capital’s investment banking services include equity financing advisory and mergers and acquisitions (M&A) advisory. Since its inception, the firm has served over one hundred clients, earning a strong reputation and positive standing in the market. Unlike most investment banks that prioritize deal volume, Sanjiang Capital places primary emphasis on achieving high completion rates for client mandates, focusing on building long-term partnerships with clients, growing alongside enterprises, and safeguarding their robust development.